Compare Novartis AG (NVS) vs Teucrium Soybean Fund (SOYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Teucrium Soybean Fund — how do they compare? Novartis AG trades at $142.74 (market cap $268.57B), while Teucrium Soybean Fund trades at $27.42 (market cap $43.52M). The key difference: Novartis AG is far larger — about 6171.2× Teucrium Soybean Fund's market cap, and Novartis AG pays a 3.31% dividend while Teucrium Soybean Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Teucrium Soybean Fund for 23 Days on average.
| NVS | SOYB | |
|---|---|---|
Market Cap | $268.57B | $43.52M |
Volume | 1,532,573 | 32,585 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $168.62 | $28.14 |
52-Week Low | $121.80 | $21.55 |
Typical Hold Time | 82 Days | 23 Days |
Enterprise Value | $309.89B | — |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Teucrium Soybean Fund
SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.
Read more on SOYB →
